Addiction & Criminology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-1518-081136


The clinical benefit of PEG-IFNa-2B consequences from the definite detail that it's extremely slowly cleared after administration, resulting in an extended terminal elimination half-life (t 1/2 ) and a far better systemic exposure (both AUC and C max ) in both preclinical and clinical studies conferring an increased efficacy compared to IFNa-2B. The pegylation of IFNa- 2B also renders the molecule less immunogenic; Pegasys ® (pegylated Interferon a) is a smaller amount immunogenic than Roferon ® (native Interferon a). The toxic kinetic profile of PEG-IFNa-2B obtained during a GLP preclinical toxicology study involving the repeated administration of the biopharmaceutical for 13 weeks by the subcutaneous route in Macaca fascicularis.

High Impact List of Articles
Conference Proceedings

Relevant Topics in Clinical Sciences

Get the App